Enbang Biotech

Enbang Biotech is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, specializing in the development of targeted protein degradation (TPD) therapies. The company leverages its proprietary En-Glue and En-PROTAC platforms to design small molecule drugs, including molecular glues and proteolysis-targeting chimeras, aimed at treating cancer and autoimmune disorders. Their lead programs focus on high-prevalence indications such as prostate and breast cancer by targeting hormone receptors and other validated oncogenic drivers. Enbang Biotech is supported by prominent venture capital firms and maintains a robust R&D focus on overcoming drug resistance in traditional small molecule inhibitors.